Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

May 14, 2020

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2028

Conditions
Diffuse Large B Cell Lymphoma
Interventions
OTHER

Prospective cohort

"Immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off\>50%), MUM1/IRF4, c-myc (cut off\>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis Radiomic analysis"

OTHER

Retrospective cohort

"Immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off\>50%), MUM1/IRF4, c-myc (cut off\>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis Radiomic analysis"

Trial Locations (4)

47014

RECRUITING

Irst Irccs, Meldola

47924

RECRUITING

Ospedale Infermi, Rimini

48121

RECRUITING

Ospedale S. Maria delle Croci RAVENNA, Ravenna

Unknown

RECRUITING

L'Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola-Malpighi, Bologna

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER